Celebrating 6 years of innovation and collaboration at JLABS Shanghai

Sophie Shen, PhD, MPA
Head, JLABS Shanghai

JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including pharmaceutical and medical technology sectors. We provide early-stage innovators access to capital-efficient lab space, resources, and wrap around services without the need to provide equity, IP or other rights or share confidential information.

JLABS Shanghai



Established in 2019, JLABS Shanghai is the pioneering JLABS facility in the Asia Pacific, located in Zhangjiang Science City. Acting as a dynamic incubator and innovation hub, JLABS Shanghai connects emerging healthcare innovators with essential resources, mentorship, and a global network to expedite the creation of impactful healthcare solutions. Over the past six years, JLABS Shanghai has fostered collaboration and growth in the biotechnology and pharmaceutical fields while maintaining a strong commitment to patient-centric innovation.

Scan the QR code to take a virtual tour

JLABS Shanghai by the numbers

As of April 2025

4,400 sq. ft.
4,400 square foot facility

120 residents
Current and alumni

$24.1B
Raised by JLABS Shanghai residents in secured and contingent funding

Our priority areas of interest

Innovative Medicine

Immunology

Gastrointestinal
- Inflammatory bowel diseases (Crohn's disease, Ulcerative colitis)

Immunodermatology
- Psoriasis
- Atopic dermatitis (AD)
- Hidradenitis suppurativa (HS)

Rheumatology
- Psoriatic arthritis
- Rheumatoid arthritis
- Sjögren's syndrome
- Systemic lupus erythematosus
- Axial psoriatic arthritis (AxPsA)
- Connective tissue disease & vasculitis
- Idiopathic inflammatory myopathies

Autoantibody (AAb) & Maternal-fetal (MFI)
- Maternal-fetal diseases
- Hemolytic disease of the fetus and newborn
- Warm autoimmune hemolytic anemia

Oncology

- Multiple myeloma
- B-cell malignancies (to include CLL)
- Myeloid malignancies (to include MDS, AML & MPN)
- Bladder cancer
- Lung cancer
- Prostate cancer
- Immune therapy

Neuroscience

Neuropsychiatry
- Depression
- Psychosis spectrum disorders

Neurodegenerative Disorders
- Alzheimer's disease
- Parkinson's disease

Ophthalmology
- Geographic atrophy (GA)
- Retinal vascular diseases (RVDs)

Discovery, product development & supply

- Small molecules
- Protein therapeutics
- Cell therapy
- siRNA therapeutics
- Gene editing
- AI & Machine Learning (ML) for discovery research
- Safety testing
- Drug delivery solutions
- Supply chain technologies

Data science & digital health

- Drug Discovery: AI & Machine Learning AI/ML approaches for target ID and validation
- AI/ML-driven molecule invention/optimization (small & large molecules)
- Advancing clinical trial design with AI/ML Precision Medicine & Digital Health
- Building holistic clinical evidence via RWE
- RWD and ML-optimized trial ops and decentralized trials
- AI/ML approaches in CMC
- GenAI to drive productivity and simplification

Cardiopulmonary

- Atrial fibrillation
- Stroke
- Acute Coronary Syndrome (ACS)
- Pulmonary Hypertension

Medtech

Technologies

- Biomaterials & biologics
- Infection prevention
- Tissue regeneration
- Digital health, AI/ML, data & analytics
- Advanced imaging & visualization
- Robotic surgery & digital solutions

Preparation, prevention, intervention, and recovery

- Cardiovascular
- Surgery
- Orthopaedics
- Vision
- Technologies
- Biomaterials & biologics
- Infection prevention
- Tissue regeneration
- Digital health, AI/ML, data & analytics
- Advanced imaging & visualization
- Robotic surgery & digital solutions

Integrated Healthcare Solutions

Interventional Oncology

- Innovative intratumoral therapies that can kill tumor cells, activate and sustain an anti-cancer immune response
- Integrated delivery procedures for minimally invasive access and innovative delivery systems including procedural planning and coordination

JLABS Shanghai residents

As of April 2025

Ab Ovo Ad Novo is engaged in researching and developing potent substances for epigenetics to advance the development of retinal pharmacotherapeutics.

Achelois Biopharma is focused on developing technologies to reprogram T cells into powerful medicine for controlling and eliminating established tumors.

Actinno Biotech is transforming academic innovations to meet unmet medical needs, featuring drug discovery in Dry eye disease and type 1 Diabetes.

Ailomics Therapeutics is a pharmaceutical R&D startup with a pioneering computational and experimental platform to discover novel targets and develop first-in-class therapeutics for the diseases of significant unmet medical needs.

AliveX Biotech combines multi-omics data with AI/ML-based computational analysis and model-informed drug development (MIDD) to develop solutions for immune-mediated diseases.

Aprinoia Therapeutics is focusing on developing novel therapies and imaging-based diagnostics for neurodegenerative diseases.

Aureka Biotechnologies is leveraging AI and digital biology to usher in a data-driven era of innovative drug discovery, transforming the landscape of immunotherapy through high-throughput, AI-driven methodologies that enhance patient outcomes.

Arctic Vision is a China-based ophthalmic biotech focusing on breakthrough therapies, with a leading portfolio covering pre- clinical stage to commercial stage products.

Belite Bio is a clinical stage drug development company specializing in innovative therapies for Stargardt's and AMD, listed in Nasdaq.

Biortus Biosciences develops world-class drug discovery platforms including recombinant protein production, structural biology, in vitro assays and screening, medicinal chemistry and process development.

BodMed aims to overcome the mucosal barriers using non-viral synthetic mRNA nano-vaccines to confer the mucosal immunity.

ChemLex aims to revolutionize medicinal chemistry, which has been relying on expert experiences and manual operation, with a proprietary AI-driven automation system.

Chimerix is a UK based cell & gene biotech company aiming to address current challenges facing cell therapies with two cutting edge technology platforms.

Cytoverse Therapeutics is an innovative biotech that focuses on novel cell and gene therapy utilizing their proprietary circular RNA platform for in situ targeted delivery.

Defand Tx is a preclinical-stage biotech focused the discovery and development of molecular glue degrader medicine, and other targeted protein degradation therapeutics.

EARNING develops advanced veterinary oncology ablation technology.

Elpis Biopharmaceuticals is developing next generation of multi-modular allogeneic immune cell therapeutics to treat solid tumors and heme cancers.

Fuchu Mingsheng Biopharmaceutical focuses on developing innovative therapies that target the Wnt signaling pathway to address and treat various inflammatory diseases.

GeneQuantum Healthcare is developing the next generation of ADCs with wider therapeutic window & higher affordability using its proprietary bioconjugation technology.

Gentas Biotechnology provides unique miniature swine platforms for drug R&D and development of gene-editing based therapeutic strategies.

Genocury is a R&D biotechnology corporation, which commits to the research of cell and gene therapies(CGT) targeting various tumor, we also expects to provide the most promising universal treatment solutions to treat cancers.

Hebe Boundless is is developing the cutting-of -edge therapeutic approaches in cancer immunotherapy through the extensive translational research gained to efficiently R&D cell and therapeutic vaccines in cancers.

Haut.AI is a technology company focusing on research and development of artificial intelligence methods for skincare and skin health applications.

Nanyang Biologics is an AI-empowered platform focusing on drug discovery from tropical medicinal herbs for the treatment and management of chronic diseases.

NEAR Brain is an AI-based medical software startup with a mission to create a future medical platform for everyone, aiming at the cerebrovascular market to provide a cerebral blood flow assessment solution to hospitals worldwide.

Pieryen Therapeutics is dedicated to innovations in therapeutic polymers and advanced carriers to address unmet medical need across the global community.

Polymed Biopharmaceuticals is a clinical stage biotech targeting undruggable proteins for unmet medical needs in autoimmunity and oncology.

Progeneer is a biotechnology company specializing in utilizing a TLR 7/8 agonist and lipid nanotechnology-based adjuvant platform to enhance cellular immune response and therapeutic efficacy against oncology and infectious diseases.

Shanghai Atlas Biotech is developing solutions that help accelerate the development and delivery of life-saving diagnostic methods and cell therapies, we aim to address some of the most pressing challenges in healthcare today.

Shanghai Helix Bioelectronics is developing a semiconductor- based diagnostic platform for high sensitivity detection and high-throughput data collection through multiplexing for the enablement of precision medicine with the aid of artificial intelligence.

Suzhou Forlong Biotechnology is a clinical stage biotech, developing pioneering Synthetic Immunology-based Cytokine therapy.

TenNor Therapeutics is a Clinical stage biotech focusing on discovery and development of therapies for diseases associated with bacterial infections.

Tranlab Therapeutics is developing game-changing technology for macrophage targeted delivery of drugs using our novel macrophage targeting molecules, which are conjugated with drugs via cleavable linkers or genetically encoded into biologics.

TriOAR is a biotech company focusing on developing next-generation antibody-based therapeutics including ADC (Antibody Drug Conjugates) and IO (Immuno-oncology) with novel platform technologies.

VSPharmTech is a clinical stage biotech committed to paradigm shift in the development of radiosensitizers by offering VS-101, a mechanism-driven synergy-equipped radiosensitizer that excels in low toxicity, thus enabling its application across various types of tumors.

xNA Biotechnologies is an innovative developer of gymnotic delivered and organ-enriched antisense oligonucleotide drug.

UT gene (formerly Stanna Tx) Focus on extrahepatic delivery to expand RNA application boundaries for novel therapy in oncology and immunology.

JLABS Shanghai
No.1 South building, JinChuang
Mansion No.4560 Jinke Road
Zhangjiang Hi-Tech Park, Pudong District
Shanghai, CN 201203

Subscribe to our newsletter
jnjinnovation.com/jlabs
@JLABS